Analytical Tool - Current & Future Lung Cancer Therapeutics

Summary

Introduction

Analytical Tool - Current & Future Lung Cancer Therapeutics is a premium combo product of "Current and Future Therapies for Lung Cancer: A Therapeutic & Competitive Insight" and "Lung Cancer Drug Pipeline Update 2006".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

Contents

• 1 Executive Summary

• 2 Cancer Highlights

• 3 Methodology

• 4 List of Contents

• 4.1 List of boxes
• 4.2 List of tables
• 4.3 Appendices

• 5 Introduction

• 5.1 Current Treatment Strategies
• 5.2 Disease Definition
• 5.3 Etiology & Pathophysiology
• 5.4 Prognosis
• 5.5 Epidemiology

• 6 Progress in current treatment strategies

• 6.1 Improvements adding microtubule inhibitor
• 6.2 Improvement of disease related symptoms in elderly patients
• 6.3 Toxicity profile favoured
• 6.4 A new formula
• 6.5 Monotherapy?
• 6.6 Failed to demonstrate a survival advantage
• 6.7 Reduction in mortality risk

• 7 Key Drug Strategies in Lung Cancer

• 7.1 Apoptosis
• 7.2 Antiangiogenesis and Antivascular Agents
  • 7.2.1 EGFR and VEGFR as target
• 7.3 Immunotherapy

• 8 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

• 8.1 Grade 4 adverse events
• 8.2 No new remarks
• 8.3 No significant effect on overall survival
• 8.4 Bristol Myers Squibb entered into an agreement
• 8.5 Many uncertainties remain
• 8.6 Development terminated
• 8.7 Continuing Enrollment
• 8.8 Apoptotic inducer
• 8.9 Fully-human monoclonal antibody
• 8.10 Eagerly awaiting data
• 8.11 Mutations and response
• 8.12 Statistically and clinically significant survival advantage
• 8.13 Anti-idiotypic monoclonal antibody
• 8.14 Shift in the development focus
• 8.15 Sensitizer
• 8.16 Treatment in earlier-stage cancer could be more effective
• 8.17 Discontinued radiosensitizer
• 8.18 Improvement in chemoradiotherapy
• 8.19 Progress on HDAC inhibitor
• 8.20 Progress Analysis Carboxyamidotriazole
• 8.21 Chemotherapy nave subjects

• 9 Disclaimer

• 9.1 Liability
• 9.2 Completeness

• 10 Appendix 1. Treatment Guide Lines

• 10.1 References

• 11 Appendix 2: Selected Company Profiles

• 11.1 Abgenix
• 11.2 Aphton
• 11.3 AstraZeneca
• 11.4 Bristol-Myers Squibb
• 11.5 Eli Lilly
• 11.6 Genentech
• 11.7 Genta
• 11.8 GlaxoSmithKline
• 11.9 ImClone
• 11.10 ISIS Pharmaceuticals
• 11.11 Ligand Pharmaceuticals
• 11.12 OSI Pharmaceuticals
• 11.13 Pfizer
• 11.14 Pharmacyclics
• 11.15 Sanofi- Aventis
• 11.16 Telik

• 12 Appendix 3 Progress profiles on approved drugs

• 12.1 Docetaxel
• 12.2 Vinorelbine
• 12.3 Gemcitabine
• 12.4 Paclitaxel
• 12.5 Pemetrexed
• 12.6 Gefitinib
• 12.7 Erlotinib

• 13 Drug Index

• 14 Company Index

• List of boxes

• Box 1: Scientific Data on Docetaxel
• Box 2: Quick Facts - Vinorelbine
• Box 3: Scientific Data on Vinorelbine
• Box 4: Quick Facts - Gemcitabine
• Box 5: Scientific Data on gemcitabine
• Box 6: Scientific Data on Pemetrexed
• Box 7: Quick Facts - pemetrexed
• Box 8: Quick Facts - Gefitinib
• Box 9: Scientific Data on Gefitinib
• Box 10: Quick Facts - Erlotinib

• List of tables

• Table 1: Chemotherapeutic drugs for treatment of NSCLC
• Table 2: Near Term Approved Drugs for the Treatment of NSCLC
• Table 3: Chemotherapy Drugs off Patent
• Table 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
• Table 5: VTA agents under development
• Table 6: EGFR or VEGFR inhibitors
• Table 7: FMS-like tyrosine kinases and their Synonyms
• Table 8: Fms-related Tyrosine Kinase Targets in Development
• Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 10: Cancer immunotherapy strategies
• Table 11: Recently presented studies Lapatinib
• Table 12: Recently presented studies ZD-6474
• Table 13: Recently presented studies vinflunine
• Table 14: Recently presented studies Panitumumab
• Table 15: Recently presented studies Genasense
• Table 16: Recently presented studies cetuximab
• Table 17: Recently presented studies bevacizumab
• Table 18: Recently presented studies bexarotene
• Table 19: Recently presented studies Xcytrin

• Appendices

• 10 Appendix 1: Treatment Guide Lines
• 11 Appendix 2: Selected Company Profiles
• 12 Appendix 3: Progress profiles on approved drugs